Artwork
iconShare
 
Manage episode 520147110 series 3702379
Content provided by American Society of Addiction Medicine. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by American Society of Addiction Medicine or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Rapid vs Standard Induction to Injectable Extended-Release Buprenorphine

JAMA Network

This industry-sponsored, multicenter, open-label randomized clinical trial with 729 participants, assessed if rapid induction (RI) for initiating extended-release buprenorphine is as safe and effective as standard induction (SI) in individuals who inject opioids or use fentanyl. RI was well tolerated and had higher retention than SI at extended-release buprenorphine injection 2 overall and in fentanyl positive participants. Administering the second extended-release buprenorphine injection 1 week after the first was well tolerated in both the RI arm and SI arm. These findings suggest support RI for extended-release buprenorphine induction in high-risk patients and demonstrate the feasibility of administering the first 2 doses at least 1 week apart.

Read this issue of the ASAM Weekly

Subscribe to the ASAM Weekly

Visit ASAM

  continue reading

100 episodes